Volume-Based Assessment With F-18-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hyun, Seung Hyup | - |
dc.contributor.author | Ahn, Hee Kyung | - |
dc.contributor.author | Ahn, Myung-Ju | - |
dc.contributor.author | Ahn, Yong Chan | - |
dc.contributor.author | Kim, Jhingook | - |
dc.contributor.author | Shim, Young Mog | - |
dc.contributor.author | Choi, Joon Young | - |
dc.date.available | 2020-02-28T08:42:54Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2015-09 | - |
dc.identifier.issn | 0361-803X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/10204 | - |
dc.description.abstract | OBJECTIVE. We evaluated the prognostic impact of volume-based assessment by pretreatment F-18-FDG PET/CT in patients who had clinical stage IIIA-N2 non-small cell lung cancer (NSCLC) treated with neoadjuvant concurrent chemoradiotherapy (CCRT) followed by surgical resection. MATERIALS AND METHODS. We reviewed 161 consecutive patients who had stage IIIA-N2 NSCLC treated with neoadjuvant CCRT followed by surgery. In all cases, N2 disease was pathologically confirmed by mediastinoscopic biopsy, endobronchial ultrasound-guided transbronchial needle aspiration, or video-assisted thoracoscopic surgery. We measured the total metabolic tumor volume (total MTV) and the maximum standardized uptake value (SUVmax), including a primary tumor and metastatic nodes on the pretreatment scan. Overall survival (OS) and disease-free survival (DFS) were assessed using the Kaplan-Meier method. The association of PET parameters with OS and DFS was determined by univariable and multivariable analyses performed using the Cox regression model. RESULTS. A higher total MTV was significantly associated with poor DFS (hazard ratio [HR], 1.82; p = 0.036) and OS (HR = 2.97; p = 0.012) in the multivariable analysis. In contrast, a higher SUVmax was not significantly associated with poor DFS and OS. Patients with a high total MTV (> 22 cm(3)) had a median survival time that was significantly shorter than that of patients with a low total MTV (median DFS, 11.3 vs 42.0 months, respectively [p < 0.001]; median OS, 38.3 months vs not reached [p < 0.001]). Kaplan-Meier curves showed significant differences on the basis of total MTV in patients with or without mediastinal downstaging after CCRT. Patients with a high total MTV had significantly worse DFS when they had post-neoadjuvant pathologic (yp) stage 0-II disease (p = 0.020) or yp stage III disease (p = 0.036). Higher total MTV was also associated with worse OS in patients with yp stage 0-II disease (p = 0.013) or yp stage III disease (p = 0.007). CONCLUSION. A higher pretreatment total MTV is associated with worse outcome, independent of yp stage, in patients with stage IIIA-N2 NSCLC treated with neoadjuvant CCRT followed by surgery. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | AMER ROENTGEN RAY SOC | - |
dc.relation.isPartOf | AMERICAN JOURNAL OF ROENTGENOLOGY | - |
dc.subject | POSITRON-EMISSION-TOMOGRAPHY | - |
dc.subject | PROGNOSTIC VALUE | - |
dc.subject | FDG PET/CT | - |
dc.subject | SURVIVAL | - |
dc.subject | TUMOR | - |
dc.subject | PARAMETERS | - |
dc.title | Volume-Based Assessment With F-18-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000359997100045 | - |
dc.identifier.doi | 10.2214/AJR.14.13847 | - |
dc.identifier.bibliographicCitation | AMERICAN JOURNAL OF ROENTGENOLOGY, v.205, no.3, pp.623 - 628 | - |
dc.identifier.scopusid | 2-s2.0-84942627433 | - |
dc.citation.endPage | 628 | - |
dc.citation.startPage | 623 | - |
dc.citation.title | AMERICAN JOURNAL OF ROENTGENOLOGY | - |
dc.citation.volume | 205 | - |
dc.citation.number | 3 | - |
dc.contributor.affiliatedAuthor | Ahn, Hee Kyung | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | F-18-FDG PET/CT | - |
dc.subject.keywordAuthor | metabolic tumor volume | - |
dc.subject.keywordAuthor | neoadjuvant concurrent chemoradiotherapy | - |
dc.subject.keywordAuthor | non-small cell lung cancer | - |
dc.subject.keywordAuthor | standardized uptake value | - |
dc.subject.keywordPlus | POSITRON-EMISSION-TOMOGRAPHY | - |
dc.subject.keywordPlus | PROGNOSTIC VALUE | - |
dc.subject.keywordPlus | FDG PET/CT | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | TUMOR | - |
dc.subject.keywordPlus | PARAMETERS | - |
dc.relation.journalResearchArea | Radiology, Nuclear Medicine & Medical Imaging | - |
dc.relation.journalWebOfScienceCategory | Radiology, Nuclear Medicine & Medical Imaging | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.